Heidi Ko/LinkedIn
May 15, 2025, 16:22
Heidi Ko: Excited to Share Labcorp’s Oncology Testing Solutions at ASCO 2025
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared a post on LinkedIn:
“We’re excited to be at this year’s 2025 ASCO Annual Meeting to share how our oncology testing solutions are helping providers deliver faster, more personalized care. With a portfolio of over 450 tests – including biomarker testing, hereditary cancer risk assessments, next-generation sequencing (NGS), and molecular disease detection – we support confident decision-making across the continuum of cancer care. Let’s connect in person to explore how we can help you improve patient outcomes.”
More posts featuring Heidi Ko.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 28, 2025, 03:49
Jul 27, 2025, 20:55
Jul 27, 2025, 19:47